# name
Impact of HIV kick-and-kill therapy on host epigenetic and transcriptional programs in PBMC, and viral rebound after cART interruption

# metadata.dc.description.abstract[].value
Background: BCN02 was a pilot kick-and-kill clinical trial that combined therapeutic vaccination (MVA.HIVconsv) with the latency reversing agent romidepsin (RMD) followed by a monitored antiretroviral pause (MAP) in 15 early-treated HIV+ individuals (NCT02616874). Out of 12 evaluable participants for an omics subanalysis, 8 participants showed early (pVL > 2000 copies/mL < 4 weeks) and 4 a more delayed viral rebound (pVL > 2000 copies/mL > 4 weeks) in MAP. Systems biology analyses identified epigenetic and molecular mechanisms associated with response to vaccination and RMD and viral rebound kinetics.

# metadata.dc.relation.ispartof[].value
Journal of the International AIDS Society, 2021, vol. 24, num. S1, p. 36-38

# metadata.dc.rights[].value
cc-by (c) Oriol-Tordera, Bruna et al., 2021

# metadata.dc.source[].value
Articles publicats en revistes (Genètica, Microbiologia i Estadística)

# metadata.dc.title[].value
Impact of HIV kick-and-kill therapy on host epigenetic and transcriptional programs in PBMC, and viral rebound after cART interruption